• 1
    Carbone PP, Bono V, Frei E 3rd, Brindley CO. Clinical studies with vincristine. Blood. 1963; 21: 640647.
  • 2
    Owellen RJ, Owens AH Jr., Donigian DW. The binding of vincristine, vinblastine and colchicine to tubulin. Biochem Biophys Res Commun. 1972; 47: 685691.
  • 3
    Owellen RJ, Hartke CA, Dickerson RM, Hains FO. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class. Cancer Res. 1976; 36: 14991502.
  • 4
    da Silva CP, de Oliveira CR, da Conceicao M, de Lima P. Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T-lymphocytes. Biochem Pharmacol. 1996; 51: 13311340.
  • 5
    Harmon BV, Takano YS, Winterford CM, Potten CS. Cell death induced by vincristine in the intestinal crypts of mice and in a human Burkitt's lymphoma cell line. Cell Prolif. 1992; 25: 523536.
  • 6
    Kobayashi H, Takemura Y, Holland JF, Ohnuma T. Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukemia cells: mechanism of inoculum effect. Biochem Pharmacol. 1998; 55: 12291234.
  • 7
    Haim N, Epelbaum R, Ben-Shahar M, Yarnitsky D, Simri W, Robinson E. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer. 1994; 73: 25152519.
  • 8
    Ronghe M, Burke GA, Lowis SP, Estlin EJ. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines. Cancer Treat Rev. 2001; 27: 327337.
  • 9
    Klumper E, Pieters R, Veerman AJ, et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood. 1995; 86: 38613868.
  • 10
    Owellen RJ, Root MA, Hains FO. Pharmacokinetics of vindesine and vincristine in humans. Cancer Res. 1977; 37(8 Pt 1): 26032607.
  • 11
    Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, Uges DR, Kamps WA, de Graaf SS. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol. 1999; 44: 203209.
  • 12
    Crom WR, de Graaf SS, Synold T, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr. 1994; 125: 642649.
  • 13
    Coukell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Drugs. 1997; 53: 520538.
  • 14
    Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep. 2001; 3: 156162.
  • 15
    Kanter PM, Klaich GM, Bullard GA, King JM, Bally MB, Mayer LD. Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs. 1994; 5: 579590.
  • 16
    Millar JL, Millar BC, Powles RL, et al. Liposomal vincristine for the treatment of human acute lymphoblastic leukaemia in severe combined immunodeficient (SCID) mice. Br J Haematol. 1998; 102: 718721.
  • 17
    Guthlein F, Burger AM, Brandl M, et al. Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. Anticancer Drugs. 2002; 13: 797805.
  • 18
    Leonetti C, Scarsella M, Semple SC, et al. In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors. Int J Cancer. 2004; 110: 767774.
  • 19
    Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res. 1990; 50: 575579.
  • 20
    Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol. 1993; 33: 1724.
  • 21
    Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 1994; 54: 28302833.
  • 22
    Mayer LD, Masin D, Nayar R, Boman NL, Bally MB. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer. 1995; 71: 482488.
  • 23
    Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer. 1995; 72: 896904.
  • 24
    Webb MS, Logan P, Kanter PM, et al. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol. 1998; 42: 461470.
  • 25
    Krishna R, Webb MS, St. Onge G, Mayer LD. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther. 2001; 298: 12061212.
  • 26
    Boman NL, Tron VA, Bally MB, Cullis PR. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol. 1996; 37: 351355.
  • 27
    Gelmon KA, Tolcher A, Diab AR, et al. Phase I study of liposomal vincristine. J Clin Oncol. 1999; 17: 697705.
  • 28
    Sarris AH, Hagemeister F, Romaguera J, et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol. 2000; 11: 6972.
  • 29
    Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med. 1995; 122: 254261.
  • 30
    Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998; 91: 39954019.
  • 31
    Cox DR. Regression models and life tables. J R Stat Soc [B]. 1972; 34: 187220.
  • 32
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1965; 53: 457481.
  • 33
    Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999; 86: 12161230.
  • 34
    Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001; 15: 163205.
  • 35
    Thomas DA, Cortes J, Kantarjian HM. New agents in the treatment of acute lymphocytic leukaemia. Best Pract Res Clin Haematol. 2002; 15: 771790.
  • 36
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344: 10381042.
  • 37
    Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004; 103: 43964407.
  • 38
    Aguayo A, Cortes J, Thomas D, Pierce S, Keating M, Kantarjian H. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer. 1999; 86: 12031209.
  • 39
    Thomas DA, Garcia-Manero G, Faderl S, et al. Preliminary results of phase I trial of sphingosomal vincristine (SV) and dexamethasone in relapsed or refractory acute lymphocytic leukemia (ALL) [abstract]. Blood. 2004; 104: 748a.
  • 40
    Rodriguez MA, Sarris A, East K, et al. A phase II study of liposomal vincristine in CHOP with rituximab for elderly patients with untreated aggressive B-cell non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol. May 2002; 21: 284a.
  • 41
    Rodriguez MA, Dang NH, Fayad L, et al. Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): follow-up results of a phase II study. Proc Am Clin Soc Oncol. 2004; 23: 745.
  • 42
    Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000; 18: 547561.
  • 43
    Cortes J, Plunkett W, O'Brien S, et al. Phase I trial of trimetrexate (TMTX) in acute leukemias. Proc Am Soc Clin Oncol. 1999; 18: 22a.
  • 44
    Kisor DF, Plunkett W, Kurtzberg J, et al. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol. 2000; 18: 9951003.
  • 45
    Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003; 102: 23792386.
  • 46
    Giles FJ, Cortes JE, Thomas DA, et al. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res. 2002; 8: 21342141.
  • 47
    Giles FJ, Cortes JE, Baker SD, et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol. 2001; 19: 762771.